# Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)

> **NCT03105596** · PHASE2 · UNKNOWN · sponsor: **Peking University** · enrollment: 46 (estimated)

## Conditions studied

- B-cell Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Chidamide plus DICE Regimen

## Key facts

- **NCT ID:** NCT03105596
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-04-11
- **Primary completion:** 2018-09-30
- **Final completion:** 2019-09-30
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2017-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03105596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03105596, "Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03105596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*